FORCE Blog

This blog will cover topics of interest that affect our community. Unless otherwise stated, the blog articles will be written by Sue Friedman, Executive Director of FORCE.

| More

Prostate cancer

September 30, 2019

My Experience As A Male Previvor

Note: In recognition of the last day of Prostate Cancer Awareness Month, the start of HBOC Week and in advance of Previvor Day, FORCE wants to remind people that men can be previvors too. Like women, men account for half of all mutation carriers. Male mutation carriers face challenges associated with their high risk for … + read more

November 28, 2018

You Don’t Need a Family History of Cancer to Benefit from Genetic Testing

by Sue Friedman Many people mistakenly believe that genetic testing for inherited mutations in BRCA1, BRCA2, Lynch Syndrome, and other genes is only appropriate for people with many cases of cancer in their family. National guidelines—based on the latest research—state otherwise. There are situations where a single case of cancer in a family is enough … + read more

November 9, 2018

Updates to the Practice Guidelines for Hereditary Cancer

by Piri Welcsh The National Comprehensive Cancer Network (NCCN) is a nonprofit network of 27 leading cancer centers. The NCCN publishes evidence-based guidelines for oncology. These guidelines help to set the standard of care. Guidelines are updated annually as new research is published.  Below we highlight several recent updates, which are important to the hereditary … + read more

October 29, 2018

PARP Inhibitors Take Center Stage

by Piri Welcsh, PhD “PARP inhibitor therapy, I think it’s fair to say, very likely would not be part of our armamentarium now had it not been for FORCE.” These were the words of Mary-Claire King, PhD as she accepted her 2018 FORCE Spirit of Empowerment award.  “Armamentarium,” I confess, was a word I had … + read more

June 17, 2018

Solving for Y: Reaching Men About Genetic Testing for Hereditary Breast, Ovarian, Pancreatic, Prostate And Related Cancers (HBOC)

by Sue Friedman Half of all people with an inherited BRCA, ATM, CHEK2, PALB2 or other mutation associated with HBOC are men. Nevertheless, the majority of awareness, research, and resources have focused on genetic testing in women. A recent article in JAMA highlights this disparity in BRCA testing between men and women. Emerging information on … + read more

April 12, 2018

PARP Inhibitors and Hereditary Cancer: What’s New?

by Sue Friedman PARP inhibitors are drugs designed specifically to treat cancers in people with certain inherited mutations, including BRCA1 and BRCA2, among others. These drugs block an enzyme – known as PARP – used by cells to repair damage to their DNA. Although these agents seem to be most effective in people with mutations—not just … + read more

September 30, 2016

HBOC Week Special: Inherited Mutations in BRCA1/2 and Related Genes More Common Than Expected in Men with Advanced Prostate Cancer

Guest blog by Heather H. Cheng, MD, PhD Researchers have long been aware that prostate cancer carries a substantial familial risk. New data (Robinson, et al Cell 2015) from the Stand Up To Cancer-Prostate Cancer Foundation International Dream Team collaborative group examined the genetic sequence of 150 tumors from men with advanced, hormone-resistant, metastatic prostate … + read more

May 27, 2016

Blog: What Do the New Guidelines from the National Comprehensive Cancer Network Mean For You?

by Lisa Rezende, PhD People with hereditary cancer face many decisions, such as whether or not to have genetic testing, choosing the best type and frequency of cancer screening, and whether or not to manage cancer risk through surgery. Health care providers look to national guidelines to give their patients advice as they make these … + read more

May 19, 2016

Updates in Research on Treating Hereditary Cancers

Note: This post which was originally published 08/4/15 was just updated on 05/19/16. In December 2014, the FDA approved the first targeted therapy for people with BRCA mutations. Lynparza, a type of medication known as a PARP inhibitor, was approved for women with a BRCA mutation to treat advanced ovarian, fallopian tube, or primary peritoneal cancer that has progressed after … + read more

August 9, 2015

Guest Blog: Attending ASCO as a Research Advocate

By Robin Karlin Thirty thousand health professionals, fabulous views of Lake Michigan and downtown Chicago, miles of escalators, fountains and crowded atriums, long lines at every Starbucks, session after session of the latest research and educational panels, and a fun evening at Shedd Aquarium. These were all part of my 2015 American Society of Clinical Oncology … + read more

Connect with others.

Call our Helpline

Our helpline offers peer support for people concerned about hereditary cancer. All calls are confidential. Call any time.

Join a Local Group

FORCE has outreach groups throughout the United States and in Essex, United Kingdom that meet periodically to offer peer support, and share resources.

FORCE:Facing Our Risk of Cancer Empowered